Company profile: Elicio Therapeutics
1.1 - Company Overview
Company description
- Provider of lymph node-targeted vaccines designed to directly target the lymph nodes to treat aggressive cancers and infectious diseases; a pharmaceutical research company developing immuno-tumor vaccines to treat cancer.
Products and services
- Immuno-Tumor Cancer Vaccine: Elicio Therapeutics develops a vaccine to treat cancer employing an immuno-tumor approach
- Infectious Disease Lymph Node-Targeted Vaccines: Vaccines engineered to directly target the lymph nodes for treating infectious diseases using lymph node-targeted delivery
- Lymph Node-Targeted Cancer Vaccines: Vaccines designed to directly target the lymph nodes to treat aggressive cancers using lymph node-targeted delivery
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Elicio Therapeutics
Fabrus
HQ: United States
Website
- Description: Provider of functional therapeutic monoclonal antibody discovery and development targeting challenging cell surface proteins, including GPCRs and ion channels, supported by a unique antibody discovery platform and multiple preclinical lead candidates against important cancer targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fabrus company profile →
Imvaq Therapeutics
HQ: United States
Website
- Description: Provider of innovative cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imvaq Therapeutics company profile →
Bio-Convert
HQ: Denmark
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on discovering and developing effective treatments for oral leukoplakia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bio-Convert company profile →
Oncternal Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage oncology treatments, developing a pipeline including ONCT-808, a ROR1-targeting autologous CAR T in Phase 1/2 for relapsed or refractory aggressive B-cell lymphoma; ONCT-534, a dual-action androgen receptor inhibitor for metastatic castration-resistant prostate cancer; and zilovertamab, a ROR1-targeting monoclonal antibody evaluated with other treatments for various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncternal Therapeutics company profile →
Miroculus
HQ: United States
Website
- Description: Provider of hands-off sample-to-answer solutions for molecular testing, delivering assay flexibility and automation via an affordable digital microfluidics platform that enables seamless workflow integration from novel molecular protocols to data analytics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Miroculus company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Elicio Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Elicio Therapeutics
2.2 - Growth funds investing in similar companies to Elicio Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Elicio Therapeutics
4.2 - Public trading comparable groups for Elicio Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →